Human anti-SARS-CoV2(N) IgG ELISA Kit |
|||
| EKF60809-48T | Biomatik Corporation | 48T | EUR 400.4 |
Human IgG antibody Laboratories manufactures the test sierologici sars cov2 lexo reagents distributed by Genprice. The Test Sierologici Sars Cov2 Lexo reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Test products are available in stock. Specificity: Test Category: Sierologici Group: Sars Cov2
Human anti-SARS-CoV2 (S) IgG ELISA Kit |
||
| MyBiosource | 10x96-Strip-Wells | EUR 3900 |
Human anti-SARS-CoV2 (S) IgG ELISA Kit |
||
| MyBiosource | 48-Strip-Wells | EUR 340 |
Human anti-SARS-CoV2 (S) IgG ELISA Kit |
||
| MyBiosource | 5x96-Strip-Wells | EUR 2045 |
Human anti-SARS-CoV2 (S) IgG ELISA Kit |
||
| MyBiosource | 96-Strip-Wells | EUR 455 |
SARS-COV2 RBD IgG Titer ELISA Kit |
||
| Novatein Biosciences, Inc. |
|
|
SARS-CoV2-N Antibody |
||
| EnoGene | N/A | EUR 276.5 |
|
Description: N/A |
||
SARS-CoV2-N Antibody |
||
| EnoGene | N/A | EUR 276.5 |
|
Description: N/A |
||
SARS CoV2 Spike S1 Antibody (Clone: ABM3D6.1G6)(13-33aa) |
|||
| MBS669600-5x01mg | MyBiosource | 5x0.1mg | EUR 1990 |
SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa) |
|||
| MBS669599-0025mg | MyBiosource | 0.025mg | EUR 225 |
SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa) |
|||
| MBS669599-01mg | MyBiosource | 0.1mg | EUR 445 |
SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa) |
|||
| MBS669599-5x01mg | MyBiosource | 5x0.1mg | EUR 1990 |
SARS COV2 Spike protein S Recombinant-Fc (AVI tag) |
|||
| MBS553732-01mg | MyBiosource | 0.1mg | EUR 490 |
SARS COV2 Spike protein S Recombinant-Fc (AVI tag) |
|||
| MBS553732-05mg | MyBiosource | 0.5mg | EUR 1570 |
anti- SARS antibody |
|||
| FNab07609 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against SARS |
|||
SARS-CoV-2 Ag Rapid Test |
|||
| HSGIA2200A1COV | Hi-Senty | 20 Tests/Kit | Ask for price |
|
Description: The SARS-CoV-2 Ag Rapid Test is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in nasal swab specimens from individualswith suspected SARS-CoV-2 infection in conjunction with clinical presentation and the results of other laboratory tests. Results are for the detection of SARS-CoV-2 Antigens. An antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or coinfection with other viruses. The agent detected may not be the definite cause of disease. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions. Negative results should be treated as presumptive and confirmed with a molecular assay, if necessary for patient management. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19. The SARS-CoV-2 Ag Rapid Test is intended for use by self-testing personnel. |
|||
SARS-CoV2 RBD |
|||
| 0571-001 | IBT Bioservices | 100 ug | EUR 493.75 |
|
Description: SARS-CoV-2 Receptor Binding Domain |
|||
SARS-CoV-2 Antigen Rapid Test |
|||
| INCP-502H | Hangzhou AllTest Biotech | 25 Tests | EUR 8.75 |
SARS-CoV-2 Antigen Rapid Test Kit |
|||
| abx294181-100g | Abbexa | 100 µg | EUR 850 |
SARS-CoV-2 Antigen Rapid Test Kit |
|||
| abx294181-20g | Abbexa | 20 µg | EUR 100 |
SARS-CoV-2 Antigen Rapid Test Kit |
|||
| abx294181-50g | Abbexa | 50 µg | EUR 450 |
SARS-CoV-2 Antigen Rapid Test Kit |
|||
| CoV2Ag-1 | UnScience | 1T | EUR 9.6 |
|
Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again. |
|||
SARS-CoV-2 Antigen Rapid Test Kit |
|||
| CoV2Ag-25 | UnScience | 25T/kit | EUR 42 |
|
Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection. |
|||
SARS-CoV-2 Antigen Rapid Test Kit |
|||
| GF101A2 | Shenzhen Lvshiyuan Biotechnology | 25 Test/kit | Ask for price |
SARS-CoV-2 Rapid Antigen Test Nasal |
|||
| 9901-NCOV-03G | Roche Diagnostics | 25 Tests/Kit | EUR 112.8 |
|
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke |
|||
